As filed with the Securities and Exchange Commission on September 22, 2025
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION
STATEMENT
UNDER THE SECURITIES ACT OF 1933
Processa Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
Delaware | 601 21st Street, Suite 300 | 45-1539785 | ||
(State or other jurisdiction of | Vero Beach, FL 32960 | (I.R.S. Employer | ||
incorporation or organization) | (Address of Principal Executive Offices) | Identification No.) |
Processa Pharmaceuticals, Inc. 2019 Omnibus Incentive Plan
(Full title of the plan)
George Ng
Chief Executive Officer
601 21st Street, Suite 300
Vero Beach, FL 32960
772-453-2899
(Name, address and telephone number of agent for service)
Copy to:
John J. Wolfel, Jr.
Foley & Lardner LLP
One Independent Drive, Suite 1300
Jacksonville, Florida 32202
(904) 359-2000
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer ☐ | Accelerated filer ☐ | |
Non-accelerated filer ☐ | Smaller reporting company ☒ | |
Emerging growth company ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
EXPLANATORY NOTE
The purpose of this Registration Statement is to register 10,000,000 additional shares of common stock, par value $0.0001 per share, of Processa Pharmaceuticals, Inc. (the “Company”) in connection with the Amended and Restated Processa Pharmaceuticals, Inc.’s 2019 Omnibus Incentive Plan (the “Plan”).
The Plan is described in the Company’s Proxy Statement for a Special Meeting of Stockholders held on September 11, 2025. An amendment to the Plan to add an additional 10,000,000 shares to the Plan was approved by the Company’s stockholders at that meeting.
Pursuant to General Instruction E of Form S-8, the contents of the Company’s Registration Statements on Form S-8 (Registration No. 333-233264), Form S-8 (Registration No. 333-257557), Form S-8 (Registration No. 333-266912) and Form S-8 (Registration No. 333-280952), including the documents incorporated by reference therein, are incorporated by reference into this Registration Statement, except as set forth below.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 3. Incorporation of Documents by Reference.
The contents of the following documents, which have previously been filed by the Company with the Securities and Exchange Commission (the “Commission”), are hereby incorporated in this Registration Statement by reference:
● | Our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 20, 2025; |
● | our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2025 and June 30, 2025 filed on May 8, 2025 and August 7, 2025, respectively; |
● | our Current Reports on Form 8-K, filed with the SEC on January 30, 2025, February 10, 2025, June 17, 2025, June 18, 2025, June 30, 2025, July 1, 2025, July 15, 2025, July 18, 2025, July 25, 2025, August 7, 2025, August 8, 2025, August 14, 2025, August 25, 2025, September 2, 2025, September 10, 2025, and September 12, 2025; and |
● | the description of our common stock contained in or incorporated into our Registration Statement on Form 8-A, filed September 17, 2020, and any amendment or report updating that description. |
Notwithstanding the foregoing, documents or portions thereof containing information furnished under Items 2.02 and 7.01 of any Current Report on Form 8-K, including the related exhibits under Item 9.01, are not incorporated by reference in this prospectus.
Item 5. Interests of Named Experts and Counsel.
The validity of the securities offered by this prospectus will be passed upon for us by Foley & Lardner LLP.
Item 8. Exhibits.
* Filed Herewith
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Vero Beach, State of Florida, on this 22nd day of September 2025.
PROCESSA PHARMACEUTICALS, INC. | ||
By: | /s/ George Ng | |
George Ng | ||
Chief Executive Officer |
Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons on September 22, 2025 in the capacities indicated.
Signature | Title | |
/s/ George Ng | Chief Executive Officer, Director (Principal Executive Officer) | |
/s/ Russell Skibsted | Chief Financial Officer | |
Russell Skipsted | (Principal Financial Officer and Principal Accounting Officer) | |
/s/ Justin Yorke | Director | |
Justin Yorke | ||
/s/ Geraldine Pannu | Director | |
Geraldine Pannu | ||
/s/ Khoso Baluch | Director | |
Khoso Baluch | ||
/s/ James Neal | Director | |
James Neal | ||
/s/ David Young, Pharm.D, Ph.D | President of Research and Development, Director | |
David Young, Pharm.D, Ph.D |